Cole Kristina A, Attiyeh Edward F, Mosse Yael P, Laquaglia Michael J, Diskin Sharon J, Brodeur Garrett M, Maris John M
Division of Oncology, Children's Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Boulevard, Philadelphia, PA 19104-4318, USA.
Mol Cancer Res. 2008 May;6(5):735-42. doi: 10.1158/1541-7786.MCR-07-2102.
MicroRNAs are small noncoding RNAs that have critical roles in regulating a number of cellular functions through transcriptional silencing. They have been implicated as oncogenes and tumor suppressor genes (oncomirs) in several human neoplasms. We used an integrated genomics and functional screening strategy to identify potential oncomirs in the pediatric neoplasm neuroblastoma. We first identified microRNAs that map within chromosomal regions that we and others have defined as frequently deleted (1p36, 3p22, and 11q23-24) or gained (17q23) in high-risk neuroblastoma. We then transiently transfected microRNA precursor mimics or inhibitors into a panel of six neuroblastoma cell lines that we characterized for these genomic aberrations. The majority of transfections showed no phenotypic effect, but the miR-34a (1p36) and miR-34c (11q23) mimics showed dramatic growth inhibition in cell lines with 1p36 hemizygous deletion. In contrast, there was no growth inhibition by these mimics in cell lines without 1p36 deletions. Quantitative reverse transcription-PCR showed a perfect correlation of absent miR-34a expression in cell lines with a 1p36 aberration and phenotypic effect after mimetic add-back. Expression of miR-34a was also decreased in primary tumors (n = 54) with 1p36 deletion (P = 0.009), but no mutations were discovered in resequencing of the miR-34a locus in 30 neuroblastoma cell lines. Flow cytometric time series analyses showed that the likely mechanism of miR-34a growth inhibition is through cell cycle arrest followed by apoptosis. BCL2 and MYCN were identified as miR-34a targets and likely mediators of the tumor suppressor phenotypic effect. These data support miR-34a as a tumor suppressor gene in human neuroblastoma.
微小RNA是一类小的非编码RNA,通过转录沉默在调节多种细胞功能中发挥关键作用。它们在多种人类肿瘤中被认为是癌基因和肿瘤抑制基因(肿瘤微RNA)。我们采用综合基因组学和功能筛选策略来鉴定小儿肿瘤神经母细胞瘤中的潜在肿瘤微RNA。我们首先鉴定了位于我们和其他人定义为在高危神经母细胞瘤中经常缺失(1p36、3p22和11q23 - 24)或获得(17q23)的染色体区域内的微小RNA。然后,我们将微小RNA前体模拟物或抑制剂瞬时转染到一组六个神经母细胞瘤细胞系中,我们对这些细胞系的这些基因组畸变进行了特征分析。大多数转染没有显示出表型效应,但miR - 34a(1p36)和miR - 34c(11q23)模拟物在具有1p36半合子缺失的细胞系中显示出显著的生长抑制。相比之下,在没有1p36缺失的细胞系中,这些模拟物没有生长抑制作用。定量逆转录 - PCR显示,在具有1p36畸变的细胞系中miR - 34a表达缺失与模拟物回补后的表型效应完全相关。在具有1p36缺失的原发性肿瘤(n = 54)中,miR - 34a的表达也降低(P = 0.009),但在对30个神经母细胞瘤细胞系的miR - 34a基因座进行重测序时未发现突变。流式细胞术时间序列分析表明,miR - 34a生长抑制的可能机制是通过细胞周期停滞继而凋亡。BCL2和MYCN被鉴定为miR - 34a的靶标,并且可能是肿瘤抑制表型效应的介导者。这些数据支持miR - 34a作为人类神经母细胞瘤中的肿瘤抑制基因。